092730 — NeoPharm Co Cashflow Statement
0.000.00%
Last trade - 00:00
- KR₩202bn
- KR₩91bn
- KR₩97bn
- 83
- 61
- 90
- 95
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | ARS |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Net Income/Starting Line | 19,245 | 18,131 | 17,713 | 17,027 | 23,213 |
Depreciation | |||||
Amortisation | |||||
Non-Cash Items | 4,706 | 5,217 | 5,456 | 5,207 | 3,519 |
Unusual Items | |||||
Other Non-Cash Items | |||||
Changes in Working Capital | -5,926 | -7,726 | -2,939 | -5,637 | -5,088 |
Change in Accounts Receivable | |||||
Change in Inventories | |||||
Change in Other Assets | |||||
Change in Accounts Payable | |||||
Change in Other Liabilities | |||||
Other Operating Cash Flow | |||||
Cash from Operating Activities | 19,224 | 17,074 | 21,681 | 18,161 | 23,263 |
Capital Expenditures | -1,798 | -730 | -478 | -806 | -20,828 |
Purchase of Fixed Assets | |||||
Purchase / Acquisition of Intangibles | |||||
Other Investing Cash Flow Items | -51,407 | -4,009 | -16,211 | -7,993 | 4,475 |
Sale of Fixed Assets | |||||
Sale/Maturity of Investment | |||||
Change in Net Investments | |||||
Purchase of Investments | |||||
Other Investing Cash Flow | |||||
Cash from Investing Activities | -53,205 | -4,739 | -16,689 | -8,800 | -16,353 |
Financing Cash Flow Items | -0.308 | 16.2 | -62.1 | 219 | 91.8 |
Other Financing Cash Flow | |||||
Total Cash Dividends Paid | |||||
Net Issuance / Retirement of Stock | |||||
Net Issuance / Retirement of Debt | |||||
Cash from Financing Activities | 31,047 | -6,569 | -9,519 | -5,750 | -5,917 |
Foreign Exchange Effects | |||||
Beginning Cash Balance | |||||
Ending Cash Balance | |||||
Net Change in Cash | -2,906 | 5,673 | -4,140 | 3,834 | 998 |